Over the past 60 years, chemotherapeutic agents that target thymidylate biosynthesis and
the enzyme thymidylate synthase (TS) have remained among the most-successful drugs …

In the past 65 years, antifolates targeting folate metabolism played a pivotal role in drug
treatment of malignant, microbial, parasitic and chronic inflammatory diseases. Drug …

Background Pemetrexed/platinum chemotherapy has been the standard chemotherapy
regimen for lung adenocarcinoma patients, but the efficacy varies considerably. Methods To …

Introduction Pleural mesothelioma (PM) is an aggressive malignancy with no identified
predictive biomarkers. We assessed whether tumor BAP1 status is a predictive biomarker for …

Thymidylate synthase is the rate-limiting enzyme required for DNA synthesis and
overexpression of this enzyme causes resistance to cancer cells. Long treatments with 5-FU …

Malignant pleural mesothelioma (MPM) is an asbestos-related cancer with a median
survival of 12 months. The MPM incidence is 1–6/100,000 and is increasing as a result of …

Mesothelioma is an insidious disease with long latency after asbestos exposure. New cases
are continually diagnosed, although levels are declining with recognition of the asbestos risk …

Drugs that target human thymidylate synthase (hTS), a dimeric enzyme, are widely used in
anticancer therapy. However, treatment with classical substrate-site-directed TS inhibitors …

Our current understanding of the mechanisms of action of antitumor agents and the precise
mechanisms underlying drug resistance is that these two processes are directly linked …

Background Expression of proton-coupled folate transporter (PCFT) is associated with
survival of mesothelioma patients treated with pemetrexed, and is reduced by hypoxia …